Largazole and its derivatives selectively inhibit ubiquitin activating enzyme (E1)

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Ungermannova, Dana ^a   Parker, Seth J ^a   Nasveschuk, Christopher G ^a,c   Wang, Wei ^a   Quade, Bettina ^a   Zhang, Gan ^a   Kuchta, Robert D ^a   Phillips, Andrew J ^b   Liu, Xuedong ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b YALE UNIVERSITY   (United States)

^c Department of Structural Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; KETONE DERIVATIVE; LARGAZOLE DERIVATIVE; TELOMERIC REPEAT BINDING FACTOR 1; UBIQUITIN; UBIQUITIN ACTIVATING ENZYME 1; UNCLASSIFIED DRUG; ADENINE; DEPSIPEPTIDE; GREEN FLUORESCENT PROTEIN; LARGAZOLE; THIAZOLE DERIVATIVE; UBE1 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ADENYLATION; ANIMAL CELL; ARTICLE; CONJUGATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SCHIZOSACCHAROMYCES POMBE; UBIQUITINATION; ANIMAL; CELL LINE; CELL STRAIN HEK293; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOBLOTTING; METABOLISM; POLYACRYLAMIDE GEL ELECTROPHORESIS;

EUKARYOTA; SCHIZOSACCHAROMYCES POMBE;

ADENINE; ANIMALS; CELL LINE; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DEPSIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME ACTIVATION; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; IMMUNOBLOTTING; MOLECULAR STRUCTURE; TELOMERIC REPEAT BINDING PROTEIN 1; THIAZOLES; TRANSFECTION; UBIQUITIN; UBIQUITIN-ACTIVATING ENZYMES; UBIQUITINATION;

EID: 84862965075     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029208     Document Type: Article

References (46)

1. Hershko A, Ciechanover A, (1982) Mechanisms of intracellular protein breakdown. Annu Rev Biochem 51: 335-364.
2. Hershko A, Ciechanover A, Rose IA, (1979) Resolution of the ATP-dependent proteolytic system from reticulocytes: a component that interacts with ATP. Proc Natl Acad Sci U S A 76: 3107-3110.
3. Haas AL, Warms JV, Hershko A, Rose IA, (1982) Ubiquitin-activating enzyme. Mechanism and role in protein-ubiquitin conjugation. J Biol Chem 257: 2543-2548.
4. Hershko A, Ciechanover A, Heller H, Haas AL, Rose IA, (1980) Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis. Proc Natl Acad Sci U S A 77: 1783-1786.
5. Hershko A, Heller H, (1985) Occurrence of a polyubiquitin structure in ubiquitin-protein conjugates. Biochem Biophys Res Commun 128: 1079-1086.
6. Chu IM, Hengst L, Slingerland JM, (2008) The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 8: 253-267.
7. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, et al. (1995) Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685.
8. Nakayama KI, Nakayama K, (2006) Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 6: 369-381.
9. Petroski MD, Deshaies RJ, (2005) Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 6: 9-20.
10. Chiba T, Tanaka K, (2004) Cullin-based ubiquitin ligase and its control by NEDD8-conjugating system. Curr Protein Pept Sci 5: 177-184.
11. Pan ZQ, Kentsis A, Dias DC, Yamoah K, Wu K, (2004) Nedd8 on cullin: building an expressway to protein destruction. Oncogene 23: 1985-1997.
12. Podust VN, Brownell JE, Gladysheva TB, Luo RS, Wang C, et al. (2000) A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. Proc Natl Acad Sci U S A 97: 4579-4584.
13. Nalepa G, Rolfe M, Harper JW, (2006) Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 5: 596-613.
14. Hoeller D, Dikic I, (2009) Targeting the ubiquitin system in cancer therapy. Nature 458: 438-444.
15. Garber K, (2005) Missing the target: ubiquitin ligase drugs stall. J Natl Cancer Inst 97: 166-167.
16. Vinitsky A, Cardozo C, Sepp-Lorenzino L, Michaud C, Orlowski M, (1994) Inhibition of the proteolytic activity of the multicatalytic proteinase complex (proteasome) by substrate-related peptidyl aldehydes. J Biol Chem 269: 29860-29866.
17. Vinitsky A, Michaud C, Powers JC, Orlowski M, (1992) Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry 31: 9421-9428.
18. Imajoh-Ohmi S, Kawaguchi T, Sugiyama S, Tanaka K, Omura S, et al. (1995) Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun 217: 1070-1077.
19. Orlowski RZ, Kuhn DJ, (2008) Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14: 1649-1657.
20. Shinohara K, Tomioka M, Nakano H, Tone S, Ito H, et al. (1996) Apoptosis induction resulting from proteasome inhibition. Biochem J 317 (Pt 2): 385-388.
21. Taori K, Paul VJ, Luesch H, (2008) Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp. J Am Chem Soc 130: 1806-1807.
22. Bowers AA, West N, Newkirk TL, Troutman-Youngman AE, Schreiber SL, et al. (2009) Synthesis and histone deacetylase inhibitory activity of largazole analogs: alteration of the zinc-binding domain and macrocyclic scaffold. Org Lett 11: 1301-1304.
23. Chen F, Gao AH, Li J, Nan FJ, (2009) Synthesis and biological evaluation of c7-demethyl largazole analogues. Chem Med Chem 4: 1269-1272.
24. Nasveschuk CG, Ungermannova D, Liu X, Phillips AJ, (2008) A concise total synthesis of largazole, solution structure, and some preliminary structure activity relationships. Org Lett 10: 3595-3598.
25. Ghosh AK, Kulkarni S, (2008) Enantioselective total synthesis of (+)-largazole, a potent inhibitor of histone deacetylase. Org Lett 10: 3907-3909.
26. Seiser T, Kamena F, Cramer N, (2008) Synthesis and biological activity of largazole and derivatives. Angew Chem Int Ed Engl 47: 6483-6485.
27. Souto JA, Vaz E, Lepore I, Poppler AC, Franci G, et al. (2010) Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues. J Med Chem 53: 4654-4667.
28. Wang B, Huang PH, Chen CS, Forsyth CJ, (2011) Total Syntheses of the Histone Deacetylase Inhibitors Largazole and 2-epi-Largazole: Application of N-Heterocyclic Carbene Mediated Acylations in Complex Molecule Synthesis. J Org Chem.
29. Ying Y, Liu Y, Byeon SR, Kim H, Luesch H, et al. (2008) Synthesis and activity of largazole analogues with linker and macrocycle modification. Org Lett 10: 4021-4024.
30. Ying Y, Taori K, Kim H, Hong J, Luesch H, (2008) Total synthesis and molecular target of largazole, a histone deacetylase inhibitor. J Am Chem Soc 130: 8455-8459.
31. Zeng X, Yin B, Hu Z, Liao C, Liu J, et al. (2010) Total synthesis and biological evaluation of largazole and derivatives with promising selectivity for cancers cells. Org Lett 12: 1368-1371.
32. Bowers A, West N, Taunton J, Schreiber SL, Bradner JE, et al. (2008) Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor. J Am Chem Soc 130: 11219-11222.
33. Ungermannova D, Gao Y, Liu X, (2005) Ubiquitination of p27Kip1 requires physical interaction with cyclin E and probable phosphate recognition by SKP2. J Biol Chem 280: 30301-30309.
34. Zeng Z, Wang W, Yang Y, Chen Y, Yang X, et al. (2010) Structural basis of selective ubiquitination of TRF1 by SCFFbx4. Dev Cell 18: 214-225.
35. Wang W, Ungermannova D, Chen L, Liu X, (2004) Molecular and biochemical characterization of the Skp2-Cks1 binding interface. J Biol Chem 279: 51362-51369.
36. Newkirk TL, Bowers AA, Williams RM, (2009) Discovery, biological activity, synthesis and potential therapeutic utility of naturally occurring histone deacetylase inhibitors. Nat Prod Rep 26: 1293-1320.
37. Knuesel M, Cheung HT, Hamady M, Barthel KK, Liu X, (2005) A method of mapping protein sumoylation sites by mass spectrometry using a modified small ubiquitin-like modifier 1 (SUMO-1) and a computational program. Mol Cell Proteomics 4: 1626-1636.
38. Kerscher O, Felberbaum R, Hochstrasser M, (2006) Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 22: 159-180.
39. Sekizawa R, Ikeno S, Nakamura H, Naganawa H, Matsui S, et al. (2002) Panepophenanthrin, from a mushroom strain, a novel inhibitor of the ubiquitin-activating enzyme. J Nat Prod 65: 1491-1493.
40. Tsukamoto S, Hirota H, Imachi M, Fujimuro M, Onuki H, et al. (2005) Himeic acid A: a new ubiquitin-activating enzyme inhibitor isolated from a marine-derived fungus, Aspergillus sp. Bioorg Med Chem Lett 15: 191-194.
41. Eldridge AG, O'Brien T, (2010) Therapeutic strategies within the ubiquitin proteasome system. Cell Death Differ 17: 4-13.
42. Yang Y, Kitagaki J, Dai RM, Tsai YC, Lorick KL, et al. (2007) Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res 67: 9472-9481.
43. Olsen SK, Capili AD, Lu X, Tan DS, Lima CD, (2010) Active site remodelling accompanies thioester bond formation in the SUMO E1. Nature 463: 906-912.
44. Lu X, Olsen SK, Capili AD, Cisar JS, Lima CD, et al. (2010) Designed semisynthetic protein inhibitors of Ub/Ubl E1 activating enzymes. J Am Chem Soc 132: 1748-1749.
45. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, et al. (2009) An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458: 732-736.
46. Brownell JE, Sintchak MD, Gavin JM, Liao H, Bruzzese FJ, et al. (2010) Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell 37: 102-111.